Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 randomized double-blind placebo-controlled study of ICVAX in treated HIV-1 infection
CTR20263393Phase 2Active
- Sponsor
- Immuno Cure
- Start
- Sep 2026
- Modality
- Prophylactic Vaccines → Vaccines & Immunotherapeutics, DNA Vaccines → Plasmid DNA → DNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in Human immunodeficiency virus infection type 1 comparing ICVAX with ICVAX placebo (2 arms). Started Sep 2026; status: active.
02
Drugs
ICVAX
03
Conditions
Human immunodeficiency virus infection type 1
Beyond the preview
Go deeper on CTR20263393.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20263393.